developed an exosome‐based antagonist featuring SIRPα variants on the exosome surface and then investigated the efficacy of systemically administered SIRPα‐exosomes in HT29 tumor‐bearing BALB/c nude mice. The gene discussed is SIRPA; the disease is neoplasm.